WASHINGTON, Sept. 8 /PRNewswire/ -- Andrew C. von Eschenbach, M.D.,
acting commissioner of the Food and Drug Administration (FDA), will present
a keynote address at 12:30-2 p.m. on Tuesday, September 26, at the
Biotechnology Industry Organization (BIO) Mid-America VentureForum in
Cleveland, OH.
Dr. von Eschenbach was named as the acting commissioner of the FDA in
September 2005. BIO President Jim Greenwood commended President Bush for
nominating Dr. von Eschenbach to be FDA commissioner and called for the
Senate to move forward with his confirmation.
"Dr. von Eschenbach's experience as a cancer surgeon and his leadership
as director of the National Cancer Institute afford him unique insights
into the critical need to advance new treatments for patients with
life-threatening illnesses," said Greenwood. "As a teacher and academician,
he appreciates the importance of education and research in achieving
scientific breakthroughs. To provide safe and effective therapies for
patients, and healthful foods for consumers, the country needs a confirmed
FDA commissioner to ensure this agency is credible, predictable, and
effective in protecting the public health. We look forward to Dr. von
Eschenbach's comments before our VentureForum."
The BIO Mid-America VentureForum is the Midwest's largest annual
gathering of biotechnology and medical device companies, venture
capitalists, angel investors, and investment bankers from across the U.S.
and Canada. Now in its fourth year, the conference will be held on
September 25-27 at the Intercontinental Hotel in Cleveland.
The conference will feature presentations by companies selected by an
advisory board consisting of representatives from the nation's leading
venture capital firms and workshops on timely issues such as state growth
initiatives, investing in cutting-edge technology such as stem cell
research and personalized medicine, and strategies for accelerating the
regulatory review process. In addition to Dr. von Eschenbach, speakers
include Ohio Governor Bob Taft and BIO President Jim Greenwood.
To register as a general attendee, please visit
http://bma.bio.org/opencms/bma/2006/registration/index.jsp . Early
registration rates end on Monday, September 11, 2006.
Registration is complimentary for credentialed news media. Advance
media registration is available at
http://www.bio.org/news/pressreg/index.asp?multiEvent=17 through September
15, 2006. On-site registration is available only to reporters and editors
working full-time for print or broadcast news organizations with valid
media credentials.
BIO represents more than 1,100 biotechnology companies, academic
institutions, state biotechnology centers and related organizations across
the United States and 31 other nations. BIO members are involved in the
research and development of healthcare, agricultural, industrial and
environmental biotechnology products. http://www.bio.org/
SOURCE Biotechnology Industry Organization
 back to top
Related links:
http://www.bio.org/
CONTACT:
Stephanie Fischer of Biotechnology Industry
Organization, +1-202-312-9263
|
